ALT Q3 2017 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+362.0% YoY

Gross Profit

-$1M-28.6% margin

Operating Income

-$31M-674.1% margin

Net Income

-$30M-651.3% margin

EPS (Diluted)

$-57.78

QoQ Revenue Growth

+92891.9%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$453,037

Balance Sheet

Total Assets

$74M

Total Liabilities

$26M

Stockholders' Equity

$49M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$993,885	+362.0%
Gross Profit	-$1M	-$1M	+6.6%
Operating Income	-$31M	-$4M	-675.8%
Net Income	-$30M	$109M	-127.4%